Paradigm Medical Industries Developing New Software for P60 UBM Device.SALT LAKE CITY -- Paradigm Medical Industries, Inc. (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). : PMED PMED Primary and Mass Education Division .OB/PMEDW.OB), a leading innovative producer of ultrasound devices for the ophthalmic and medical industries, disclosed today it is developing the next generation of Ultrasound software for its P60 Ultrasound BioMicroscope (UBM UBM United Business Media Plc (London)
UBM Under-Bump Metallization
UBM UniCredit Banca Mobiliare S.p.A. (Italy)
UBM United Bikers of Maine
UBM Unbalanced Magnetron
UBM Ultimate Building Machine ) through a partnership with Reliacon Global, Inc. (RGI RGI Ragnar Granit Institute
RGI Resource Group International
RGI Regional Geographical Initiative
RGI Reactant Gas Inlet ). A prototype of the new software will be available at the upcoming American Society of Cataract and Refractive refractive
capacity to refract light.
a difference between the focal length of the cornea and lens, and the length of the eye, resulting in myopia or hyperopia. Surgeons' (ASCRS ASCRS American Society of Cataract and Refractive Surgery
ASCRS American Society of Colon and Rectal Surgeons ) Conference in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , beginning April 28, 2007.
"Although we already have exceptional Ultrasound imaging technology, the Company felt there is opportunity for significant improvement through a developmental program with RGI," said Paradigm Medical's Chief Executive Officer, Raymond Cannefax. "We also believe there is a need to improve our database management system. With the patient record management changes taking place throughout the medical industry, the Company decided to get ahead of the curve and help establish the benchmark for imaging related ophthalmic patient database management."
The P60 UBM is Paradigm Medical's fourth-generation device that is a sophisticated microprocessor-based, multi-frequency Ultrasound BioMicroscope that allows practitioners to acquire and view high-resolution images of the anterior segment The anterior segment is the front third of the eye that includes the structures in front of the vitreous humour: the cornea, iris, ciliary body, and lens. 
Within the anterior segment are two fluid-filled spaces:
Reliacon Global, Inc., is a venture founded by Dr. Bert Massie, former chief executive of Massie Laboratories, Inc. Dr. Massie and his team originally developed the image capture and database management system utilized in the Massie Laboratories RetCam pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children.
Of or relating to pediatrics. ophthalmic imaging device.
The new software will be installed in all new P60 UBM's delivered by the Company after July 2007. The new software will also be made available to the current owners of the P60 devices placed into service globally since the P60 was introduced in 2005.
Upon completion of the new P60 software project, RGI will begin redesigning the functionality of the Company's LD400 AutoPerimeter. "Paradigm Medical has been the leader in the field of Kinetic Fixation visual field analysis and will continue to remain in the lead with the anticipated new look and functionality of the LD400," Mr. Cannefax noted. The LD400 AutoPerimeter is used to measure patient visual fields.
Paradigm Medical Industries, Inc. (Salt Lake City, UT), currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company is a leading developer of Ultrasound devices, and has been dubbed "The UBM Company" (Ultrasound BioMicroscope). Contact us at 801-977-8970 or visit us at www.paradigm-medical.com.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.